Although the MT2A expression level in CRC may be related to tumor heterogeneity and further studies are needed to explore the reasons for this phenomenon, our results suggested that MT2A is a promising therapeutic target for colorectal cancer. This evidence concerns the gene MT2A and neoplasm.